On this page
Clobetasol Propionate Cream USP, 0.05%
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Clobetasol Propionate | .5 mg/g | 861490 | View |
Forms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Corticosteroid Hormone Receptor Agonists [MoA] | MoA | All 215 members |
| Corticosteroid [EPC] | EPC | All 215 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 212982-001 | CLOBETASOL PROPIONATE | CREAM | CLOBETASOL PROPIONATE | Prescription | AB1 | RS |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Original application | 1 | Approved | August 28, 2020 | Standard |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260909). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE: Clobetasol propionate cream USP, 0.05% is super-high potency corticosteroid formulation indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 g /week because of the potential for the drug to suppress the hypothalamic-pituitary- adrenal (HPA) axis. Use in pediatric patients under 12 years of age is not recommended. As with other highly active corticosteroids, therapy should be discontinued when control has been achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Apply a thin layer of clobetasol propionate cream to the affected skin areas twice daily and rub in gently and completely. (See INDICATIONS AND USAGE ). Clobetasol propionate cream is super- high potency topical corticosteroids; therefore, treatment should be limited to 2 consecutive weeks and amounts greater than 50 g / week should not be used . As with other highly active corticosteroids, therapy should be discontinued when control has been achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary. Clobetasol propionate cream should not be used with occlusive dressings. Geriatric Use: In studies where geriatric patients (65 years of age or older, see PRECAUTIONS ) have been treated with clobetasol propionate cream, safety did not differ from that in younger patients; therefore, no dosage adjustment is recommended.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS: Clobetasol propionate cream USP, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS: In controlled clinical trials, the most frequent adverse reactions reported for clobetasol propionate cream were burning and stinging sensation in 1% of treated patients. Less frequent adverse reactions were itching, skin atrophy, and cracking and fissuring of the skin. Cushing's syndrome has been reported in infants and adults as a result of prolonged use of topical clobetasol propionate formulations. The following additional local adverse reactions have been reported with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings and higher potency corticosteroids. These reactions are listed in an approximately decreasing order of occurrence: dryness, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, irritation, striae, and miliaria. To report SUSPECTED ADVERSE REACTIONS, contact Encube Ethicals Private Limited at 1-833-285-4151 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Description
openFDA Drug LabelingDESCRIPTION: Clobetasol Propionate Cream USP contains the active compound clobetasol propionate, a synthetic corticosteroid, for topical dermatologic use. Clobetasol, an analog of prednisolone, has a high degree of glucocorticoid activity and a slight degree of mineralocorticoid activity. Chemically, clobetasol propionate is (11β, 16β)-21-chloro-9-fluoro-11-hydroxy-16-methyl-17-(1-oxopropoxy)-pregna-1,4-diene-3,20-dione, and it has the following structural formula: Clobetasol propionate has the molecular formula C 25 H 32 ClFO 5 and a molecular weight of 467. It is a white to cream-colored crystalline powder insoluble in water. Clobetasol propionate cream USP, 0.05% contains clobetasol propionate 0.5 mg/g in a cream base of propylene glycol, mono- and di-glycerides, cetostearyl alcohol, stearoyl macrogolglycerides, white wax, chlorocresol, sodium citrate, anhydrous citric acid, and purified water. structure.jpg
Overdosage
openFDA Drug LabelingOVERDOSAGE: Topically applied clobetasol propionate cream can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS).
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED: Clobetasol Propionate Cream USP, 0.05% is supplied in 15 g tube (NDC 21922-016-04) 30 g tube (NDC 21922-016-05) 45 g tube (NDC 21922-016-06) 60 g tube (NDC 21922-016-07) Store cream between 15° and 30°C (59°-86°F). Clobetasol propionate cream should not refrigerated. Made in Italy, formulated in India. Manufactured by: Encube Ethicals Pvt. Ltd. Plot No. C-1, Madkaim Industrial Estate, Madkaim, Post: Mardol, Ponda, Goa - 403 404, India. OR Manufacture by: Encube Ethicals Pvt. Ltd. Plot No. 113, Smart Industrial Park, Pithampur, District: Dhar – 454 774, Madhya Pradesh, India. Distributed by: Encube Ethicals, Inc. 200 Meredith Drive, Suite 202 Durham, NC 27713 USA Rev: 12/23
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: CLOBETASOL PROPIONATE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 50090-5979-0 | 50090-5979 | A-S Medication Solutions | 30 g in 1 TUBE (50090-5979-0) | May 6, 2022 |
| 50090-7392-0 | 50090-7392 | A-S Medication Solutions | 15 g in 1 TUBE (50090-7392-0) | October 23, 2024 |
| 71335-2821-1 | 71335-2821 | Bryant Ranch Prepack | 60 g in 1 TUBE (71335-2821-1) | October 22, 2025 |
| 72162-2300-2 | 72162-2300 | Bryant Ranch Prepack | 15 g in 1 TUBE (72162-2300-2) | October 1, 2020 |
| 72162-2300-3 | 72162-2300 | Bryant Ranch Prepack | 30 g in 1 TUBE (72162-2300-3) | October 1, 2020 |
| 72162-2300-4 | 72162-2300 | Bryant Ranch Prepack | 45 g in 1 TUBE (72162-2300-4) | October 1, 2020 |
| 72162-2300-6 | 72162-2300 | Bryant Ranch Prepack | 60 g in 1 TUBE (72162-2300-6) | October 1, 2020 |
| 21922-016-04 | 21922-016 | Encube Ethicals, Inc. | 15 g in 1 TUBE (21922-016-04) | October 1, 2020 |
| 21922-016-05 | 21922-016 | Encube Ethicals, Inc. | 30 g in 1 TUBE (21922-016-05) | October 1, 2020 |
| 21922-016-06 | 21922-016 | Encube Ethicals, Inc. | 45 g in 1 TUBE (21922-016-06) | October 1, 2020 |
| 21922-016-07 | 21922-016 | Encube Ethicals, Inc. | 60 g in 1 TUBE (21922-016-07) | October 1, 2020 |
| 72603-323-01 | 72603-323 | Northstar Rx LLC | 15 g in 1 TUBE (72603-323-01) | November 1, 2024 |
| 72603-323-02 | 72603-323 | Northstar Rx LLC | 30 g in 1 TUBE (72603-323-02) | November 1, 2024 |
| 72603-323-03 | 72603-323 | Northstar Rx LLC | 45 g in 1 TUBE (72603-323-03) | November 1, 2024 |
| 72603-323-04 | 72603-323 | Northstar Rx LLC | 60 g in 1 TUBE (72603-323-04) | November 1, 2024 |
| 70518-4374-0 | 70518-4374 | REMEDYREPACK INC. | 30 g in 1 TUBE (70518-4374-0) | June 27, 2025 |
| 50090-5979 | 50090-5979 | A-S Medication Solutions | — | October 1, 2020 |
| 50090-7392 | 50090-7392 | A-S Medication Solutions | — | October 1, 2020 |
| 71335-2821 | 71335-2821 | Bryant Ranch Prepack | — | October 1, 2020 |
| 72162-2300 | 72162-2300 | Bryant Ranch Prepack | — | October 1, 2020 |
| 21922-016 | 21922-016 | Encube Ethicals, Inc. | — | October 1, 2020 |
| 72603-323 | 72603-323 | Northstar Rx LLC | — | November 1, 2024 |
| 70518-4374 | 70518-4374 | REMEDYREPACK INC. | — | June 27, 2025 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 11 sections on this page.